Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Killip class at presentation and immediate versus staged multivessel PCI in patients with STEMI.

Scientific reports·2026
Same author

Trend Analyses on Interventional Treatment of Atrial Fibrillation From 2016 to 2022: Insights From a Multicenter Hospital Database of Left Atrial Catheter Ablation Cases.

Clinical cardiology·2026
Same author

Impact of renal dysfunction on immediate versus staged revascularization of non-culprit lesions in patients with ST segment elevation myocardial infarction: a pre-specified subgroup analysis of the randomized MULTISTARS AMI trial.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Immunoadsorption in dilated cardiomyopathy: the IASO-DCM trial.

European heart journal·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Characteristics and outcomes of patients with heart failure and reduced left ventricular ejection fraction in relation to sodium-glucose cotransporter-2 inhibitor treatment: real-world data from the multicentre H<sup>2</sup>-registry.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Related Experiment Video

Updated: Jul 9, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

Immunoadsorption in dilated cardiomyopathy.

Alexander Staudt1, Stephan B Felix

  • 1Department of Internal Medicine B, University of Greifswald, Germany. staudt@uni-greifswald.de

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|November 27, 2007
PubMed
Summary

Immunoadsorption therapy may improve cardiac function in patients with dilated cardiomyopathy (DCM) by removing harmful cardiac autoantibodies. This approach shows promise for treating this common heart muscle disease.

More Related Videos

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Experiment Videos

Last Updated: Jul 9, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Area of Science:

  • Cardiology
  • Immunology
  • Pathophysiology

Background:

  • Dilated cardiomyopathy (DCM) is a myocardial disease defined by ventricular dilation and impaired contractile function.
  • Immune system disturbances, including autoantibodies targeting cardiac proteins, are implicated in DCM pathogenesis.
  • These cardiac autoantibodies may actively contribute to the cardiac dysfunction observed in DCM patients.

Purpose of the Study:

  • To investigate the potential of immunoadsorption to improve hemodynamic function in DCM patients.
  • To assess the impact of removing cardiac autoantibodies on left ventricular function in DCM.

Main Methods:

  • Utilizing immunoadsorption techniques to selectively remove cardiac autoantibodies from the blood of DCM patients.
  • Evaluating hemodynamic parameters and left ventricular function before and after treatment.

Main Results:

  • Preliminary studies with limited patient cohorts suggest that immunoadsorption leads to improvements in left ventricular function.
  • The removal of cardiac autoantibodies via immunoadsorption may be a viable therapeutic strategy.

Conclusions:

  • Immunoadsorption therapy demonstrates potential for improving cardiac function in dilated cardiomyopathy.
  • Targeting cardiac autoantibodies through immunoadsorption offers a promising avenue for managing DCM and its associated cardiac dysfunction.